Hepatitis B News and Research

Latest Hepatitis B News and Research

Columbia University, FairChoice Systems sign agreement to market student health information system

Columbia University and FairChoice Systems, Inc. have signed a multi-year commercialization agreement that will bring to market a cost-effective, online student health information system developed and implemented by Columbia University's own Student Health Services.

2 Mar 2010

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Spanish researchers determined that rats treated with recombinant ghrelin displayed a reduction in liver fibrosis. Ghrelin, a stomach hormone, reduced the amount of fibrogenic cells by 25% in the treated rodents. Research further showed ghrelin prevented acute liver damage and reduced oxidative stress and inflammation in the animal models.

1 Mar 2010

Hygafem announces name change to WellBeing

Hygafem, the Georgia-based premier provider of full-service hygiene technologies, announced today that the company has changed its name to WellBeing. WellBeing is introducing a new and evolving touch-free hygiene and organizational wellness platform that communicates the company’s ongoing commitment to “green” hygiene services, excellence and innovation.

27 Feb 2010

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Widely used biomarkers are not optimal in early detection of liver cancer, the third most common cause of cancer-related death worldwide, according to a new study published in this month's Gastroenterology.

26 Feb 2010

Surge in volunteers without overall coordination can make devastating situation worse instead of better

A surge in volunteers following a major disaster can overwhelm a response system, and without overall coordination, can actually make a situation worse instead of better. The outpouring of medical volunteers who responded to the devastating earthquake that rocked Haiti in January provides a roadmap for health care providers during future disasters, say the authors of a New England Journal of Medicine "Perspectives" piece that will be published online February 24.

26 Feb 2010

Combining DCP and AFP biomarkers may improve early detection of liver cancer

While biomarkers are needed to complement ultrasound in the early detection of hepatocellular carcinoma (HCC; liver cancer), neither des-gamma-carboxy prothrombin (DCP) nor the most widely used biomarker, alpha fetoprotein (AFP), is optimal, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

26 Feb 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from an ongoing Phase II study demonstrating that 73% of hepatitis C patients treated with 200 mg ANA598 twice daily in combination with pegylated interferon and ribavirin (SOC) achieved undetectable levels of virus (<15 IU/mL) at week 12, known as complete Early Virological Response or cEVR.

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Lack of knowledge and awareness impeding efforts to control HBV and HCV

A recent report by the Institute of Medicine (IOM) confirmed that 3.5 to 5.3 million people (1-2 % of the U.S. population) have chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Despite efforts by federal, state and local government agencies to control and prevent these diseases, they remain a serious public health concern. The major factor impeding efforts to control HBV and HCV is lack of knowledge and awareness among health care providers, social service professionals, members of the public, and policy-makers.

24 Feb 2010

Mouse study provides new way to test novel therapies for liver infections

How do you study-and try to cure in the laboratory-an infection that only humans can get? A team led by Salk Institute researchers does it by generating a mouse with an almost completely human liver.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Haitian President says up to 300,000 people could have died in quake

The major earthquake in January in Haiti could have killed as many as 300,000 people, an estimate that includes bodies buried in the rubble, Haitian President Rene Preval said on Sunday at a meeting of Latin American and Caribbean leaders in Mexico, Reuters reports.

23 Feb 2010

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication or stop therapy altogether. But now, scientists in Duke University's Institute for Genome Sciences & Policy have discovered two genetic alterations linked to a benign enzyme condition that keep some patients anemia-free.

21 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

AltraVax acquires vaccine development technology package from Maxygen

AltraVax, Inc., a new, privately-held biopharmaceutical company, has acquired a vaccine development technology package from Maxygen, Inc. that gives AltraVax an exclusive license to develop vaccines for infectious diseases and is targeting influenza, a treatment for hepatitis B and HIV.

18 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Hepatitis B News and Research

Latest Hepatitis B News and Research

Columbia University, FairChoice Systems sign agreement to market student health information system

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Hygafem announces name change to WellBeing

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Surge in volunteers without overall coordination can make devastating situation worse instead of better

Combining DCP and AFP biomarkers may improve early detection of liver cancer

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Lack of knowledge and awareness impeding efforts to control HBV and HCV

Mouse study provides new way to test novel therapies for liver infections

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Haitian President says up to 300,000 people could have died in quake

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

FDA approves Rituxan-FC combination therapy for CLL

AltraVax acquires vaccine development technology package from Maxygen

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis B News and Research

Latest Hepatitis B News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in